Olabir 150mg Tablet (Olaparib)

Olabir 150mg Tablet contains olaparib, an anticancer medicine called a PARP inhibitor. PARP enzymes help cells repair certain types of DNA damage. By inhibiting PARP, olaparib can make it harder for susceptible cancer cells to repair damaged DNA, which may lead to cancer-cell death. It is used in selected patients with cancers such as ovarian, breast, pancreatic and prostate cancer, depending on the disease setting and biomarker profile. BRCA1/BRCA2 or other homologous-recombination related testing may be important before treatment. Olabir 150mg Tablet is a prescription medicine and should be started and monitored by an oncologist. Treatment choice, dose, duration and combination therapy depend on the cancer type, previous treatment, laboratory results and the patient’s overall condition.

Olaparib exploits a concept called synthetic lethality: tumour cells that already have impaired homologous-recombination DNA repair, such as certain BRCA1/BRCA2-altered cancers, can become especially dependent on PARP-mediated repair and may be more vulnerable to PARP inhibition.
For current Olabir 150mg Tablet availability, in the present day, a licensed pharmacy or authorized oncology medication supplier in India could be consulted. Availability of the medication must be established before ordering, and its use must be on the recommendation of the oncologist alone.​

Olaparib is used in selected patients with cancers in which PARP inhibition has demonstrated benefit. These include certain advanced or recurrent ovarian, fallopian-tube and primary peritoneal cancers, including maintenance settings; selected HER2-negative breast cancers associated with germline BRCA mutations; selected metastatic pancreatic cancer with germline BRCA mutations after appropriate platinum-based treatment; and selected metastatic castration-resistant prostate cancer with qualifying homologous-recombination repair gene alterations. The exact indication and whether olaparib is used alone or with another anticancer medicine vary by regulatory label and clinical setting. Biomarker testing is therefore important. Olaparib should not be used simply because a tumour is described as “BRCA-like” without appropriate specialist assessment and validated testing.

Olaparib inhibits PARP1, PARP2 and PARP3, enzymes involved in repairing single-strand DNA breaks. When PARP is blocked, unrepaired DNA damage can convert into more serious double-strand breaks during cell division. Tumour cells with impaired homologous-recombination repair - including many cancers with pathogenic BRCA1/BRCA2 alterations - may be unable to repair this damage effectively. The combination of an existing DNA-repair defect and PARP inhibition can selectively push susceptible cancer cells toward death, a concept known as synthetic lethality. Normal cells with intact repair pathways may be better able to tolerate this stress, although clinically important toxicity can still occur.

Evidence context: The studies below are pivotal or widely cited evidence supporting the olaparib in major treatment settings. Trial results should not be interpreted as a guarantee of benefit for an individual patient, and exact eligibility must match the current approved indication and oncology guideline.

Olabir 150mg Tablet may cause side effects, and their frequency varies by indication, dose, combination regimen and patient population. The list below highlights clinically important effects rather than assigning a single percentage across different trials.

For olaparib tablets, the usual adult dose is 300 mg orally twice daily (two 150 mg tablets per dose), approximately 12 hours apart, with or without food. Dose reductions for toxicity are commonly 250 mg twice daily and then 200 mg twice daily. For moderate renal impairment (creatinine clearance 31-50 mL/min), the labelled dose is 200 mg twice daily. If a strong CYP3A inhibitor cannot be avoided, the FDA label recommends reducing olaparib to 100 mg twice daily; with a moderate CYP3A inhibitor, 150 mg twice daily. These are molecule-level label doses; the oncologist must confirm the exact regimen for the patient’s cancer and combination treatment.

Administration guidance: Take Olabir 150mg Tablet exactly as prescribed by your oncologist, usually on a regular twice-daily schedule for tablet formulations. Swallow the tablets whole and do not crush, chew or split them unless the product information specifically permits it. They may generally be taken with or without food. Try to take doses at approximately the same times each day. Your doctor may interrupt treatment or reduce the dose if significant side effects or blood-count abnormalities occur. Regular complete blood counts and other laboratory tests are required during therapy. Avoid grapefruit, Seville oranges and products containing them unless your oncology team says otherwise because they may alter olaparib exposure. Never change the dose or stop treatment on your own.

If a dose is missed, take the next dose at the regularly scheduled time. Do not take an extra dose to make up for the missed dose. If vomiting occurs after a dose, do not repeat it; take the next scheduled dose at the usual time.

Before treatment and during therapy, monitor complete blood count (CBC); the FDA/EMA labels recommend at least monthly CBC monitoring. Assess renal function before treatment and periodically. Liver tests should be considered, particularly if symptoms suggest hepatic injury. Evaluate persistent cytopenias, new respiratory symptoms and signs of thrombosis promptly.
Practical monitoring checklist
• Complete blood count (CBC) at the label/protocol-recommended intervals
• Liver function according to baseline risk and treatment label
• Renal function and hydration/renal toxicity assessment as clinically indicated

1. FDA Lynparza (olaparib) Prescribing Information, current label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208558s010lbl.pdf
2. EMA Lynparza Product Information / SmPC. Https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf
3. Journals of clinical oncology. Overall survival results from polo trials. Https://pmc.ncbi.nlm.nih.gov/articles/PMC10476841/
4. National Institute of health. Olaparib. Https://pmc.ncbi.nlm.nih.gov/articles/PMC8190876/.
5. Touchoncology. Impressive result for olaparib therapy. https://touchoncology.com/insight/results-from-solo-1-presented-at-esmo-2018-impressive-findings-for-olaparip-maintenance-therapy-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovarian-cancer/.